HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tirschwell, D. Search for Related Content PubMed Articles by Tirschwell, D.

Combined treatment with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke

Design
Two^* randomised (allocation concealed), blinded {patients, clinicians, data collectors, outcome assessors, data analysts, and manuscript writers}, placebo controlled trials with a mean follow up of 3.9 years (Perindopril Protection against Recurrent Stroke Study [PROGRESS]).

Setting
172 centres from 10 countries.

Patients
6105 patients (mean age 64 y, 70% men) who had a history of stroke or TIA in the previous 5 years, had no definite indication for or contraindication to an angiotensin-converting enzyme (ACE) inhibitor, and were clinically stable for 2 weeks after their most recent vascular event. 6102 patients (> 99%) completed follow up for fatal events.

Intervention
Some patients were allocated to perindopril 4 mg daily (n=1281) or to single placebo (n=1280). Other patients, for whom the responsible physician found no specific indication for or contraindication to a diuretic, were allocated to perindopril plus indapamide (indapamide dose 2.0 or 2.5 mg daily) (n=1770) or to double placebo (n=1774).

Main outcome measures
Fatal . . . [Full text of this article]

David Tirschwell, MD, MSc

University of Washington School of Medicine Seattle, Washington, USA